A treatment to prevent blindness in people suffering from diabetic retinopathy, PolyPhotonix’s Noctura 400 sleep mask, has been adopted by Ashford and St Peter’s NHS Foundation Trust.
Shown to improve patients’ visual acuity, the mask could potentially save the NHS millions of pounds a year.
Backed by the RENDER Study, the sleep mask has demonstrated improvement and stabilisation of diabetic eye disease in 96% of patients. It is an early-stage non-invasive alternative to current, later-stage invasive treatments such as eye injections for patients with the condition; which is a leading cause of blindness in Europe.
Based on research undertaken by Ashford and St Peter’s NHS Foundation Trust, improving patient outcomes with an earlier stage intervention could save the NHS £3,000 per patient. It is believed that the sleep mask could deliver cost savings estimated more than £180 million per year if adopted across the NHS.
Diabetes costs the NHS around £10 billion a year, most of which goes in treating complications, including eyesight damage.
The current NHS pathway involves monitoring patients with early signs of diabetic retinopathy until their eyes deteriorate and they qualify for treatment intervention. However, the Noctura 400 sleep mask uses intervention at an early stage to prevent future problems before they start.
The sleep mask treatment can be worn during normal hours of sleep and can prevent the need for expensive and time intensive injections directly into the eyeball, which can be stressful and unpleasant for patients, and comes with a risk of side effects.
The mask maintains or improves patient’s vision and the physiological effects of diabetes on their eyes by delivering a precise level of light at a particular wavelength during a patient’s normal hours of sleep in a home-based setting. Noctura 400 administers low-level light to prevent the eyes’ increased demand of oxygen at night and reduces the damaging effects of diabetic retinopathy on patients’ eyesight.
Mr Ulrich Meyer-Bothling, consultant ophthalmic surgeon at Ashford and St Peter’s Hospitals NHS Foundation Trust, said: “The Trust’s decision to offer the sleep mask as part of its diabetic retinopathy pathway is great news for patients and the NHS alike.
“For patients, it represents a pain-free treatment option for their condition. It is non-invasive, and they are, in effect, treated whilst they sleep. It also doesn’t require patients to attend the hospital as frequently, giving them more of their time back. It represents a gentler approach to treating or even preventing diabetic retinopathy and diabetic macular oedema. I’m proud that most of the patients I have treated with the mask have shown stabilisation and improvement in their diabetic eye disease.”
Richard Kirk, chief executive of PolyPhotonix, added: “For the NHS, treating diabetic retinopathy patients with the Noctura 400 sleep mask represents a cost-effective alternative to existing treatments. At a time when our healthcare budgets are already stretched, adding the sleep mask to existing care pathways makes sound financial sense in helping healthcare services recover from the pandemic and freeing up hospital appointments for those in greater need of emergency care.
“Most importantly, it prevents problems before they arise and enables doctors to improve patient care.”
